Twin Lakes Capital Management LLC Sells 2,188 Shares of Gilead Sciences, Inc. $GILD

Twin Lakes Capital Management LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 60,328 shares of the biopharmaceutical company’s stock after selling 2,188 shares during the quarter. Gilead Sciences makes up 3.3% of Twin Lakes Capital Management LLC’s holdings, making the stock its 4th largest holding. Twin Lakes Capital Management LLC’s holdings in Gilead Sciences were worth $6,689,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of GILD. Smallwood Wealth Investment Management LLC acquired a new position in shares of Gilead Sciences in the 1st quarter worth $25,000. Activest Wealth Management grew its holdings in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares in the last quarter. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences during the second quarter valued at $27,000. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences during the first quarter valued at $29,000. Finally, Colonial Trust Advisors grew its holdings in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 213 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer owned 591,203 shares of the company’s stock, valued at $66,013,726.98. The trade was a 1.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This represents a 1.57% decrease in their position. The disclosure for this sale can be found here. Insiders sold 61,500 shares of company stock valued at $7,142,140 over the last quarter. Insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on GILD. UBS Group lifted their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the company from $108.00 to $127.00 in a report on Friday, August 8th. Wolfe Research lifted their price target on Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a report on Thursday. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Finally, Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a report on Tuesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $122.61.

Gilead Sciences Price Performance

GILD opened at $120.94 on Monday. The stock has a market cap of $150.06 billion, a price-to-earnings ratio of 24.09, a PEG ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a fifty day moving average price of $115.47 and a 200 day moving average price of $111.11.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.